News Release
2021.03.01
Presentation of STEMTRA Phase 2 Trial Results at the 44th Annual Meeting of the Japan Society of Neurotraumatology
Info
2021.02.22
Head of Regulatory Affairs Japan, Kazumi Sawaguchi, Ph.D., gave a presentation at 5th DIA Cell and Gene Therapy Products Symposium in Japan
Info
2021.01.06
SanBio to Present at the 39th Annual J.P. Morgan Healthcare Conference
News Release
2021.03.01
Presentation of STEMTRA Phase 2 Trial Results at the 44th Annual Meeting of the Japan Society of Neurotraumatology
News Release
2021.01.05
Publication of STEMTRA Phase 2 Interim Analysis for SB623 in Neurology
News Release
2020.12.15
The status of domestic approval filing for regenerative cell medicine SB623 for treatment of chronic effects associated with traumatic brain injury
Info
2021.02.22
Head of Regulatory Affairs Japan, Kazumi Sawaguchi, Ph.D., gave a presentation at 5th DIA Cell and Gene Therapy Products Symposium in Japan
Info
2021.01.06
SanBio to Present at the 39th Annual J.P. Morgan Healthcare Conference
Info
2019.12.16
Message from Representative Director and President, Keita Mori, regarding disclosures made on December 13, 2019
As a global leader in regenerative cell medicine, SanBio works to develop pharmaceuticals, such as SB623, that can be delivered to patients all over the world. SB623 represents just the first step in this effort, but we believe it will serve as a foundation on which we can build to support the health of a large number of patients in the future.